---
title: "European Biotech: Innovation in AMR needs a viable market"
description: A Q&A with Henr Skinner in European Biotech magazine.
---

 April 3, 2025

[In the News](https://www.amractionfund.com/blog/tag/in-the-news)

# European Biotech: Innovation in AMR needs a viable market

AMR Action Fund CEO Henry Skinner participated in a wide-ranging Q&A with European Biotech that touched on the market challenges antimicrobial developers face and the global landscape of antibiotic innovation.

“What really concerns me is that in the absence of a viable market, all of the early-stage grant funding and R&D will be for naught. There is an adage that 'you can’t push a rope,' and this applies to financing innovation to address the issues of antimicrobial resistance,” Dr. Skinner said. He added, “If Europe can get the right pull incentives in place, I think it would send a strong message to investors and give an advantage to the small antimicrobial companies that are doing very good work and leading innovation across Europe.”

Read the [full interview here](https://european-biotechnology.com/magazines/2025/deeptech-bioeconomy-the-battle-for-green-solutions/).  

![](https://www.amractionfund.com/hubfs/raw_assets/public/amr-action-fund/images/contact-bg-img.png)

## Connect With Us

[ Contact ](https://www.amractionfund.com/blog/european-biotech-innovation-in-amr-needs-a-viable-market#)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "admin",
    "url" : "https://www.amractionfund.com/blog/author/admin"
  },
  "dateModified" : "2025-04-03T15:38:30.746Z",
  "datePublished" : "2025-04-03T15:38:30.000Z",
  "headline" : "European Biotech: Innovation in AMR needs a viable market",
  "mainEntityOfPage" : {
    "@id" : "https://www.amractionfund.com/blog/european-biotech-innovation-in-amr-needs-a-viable-market",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject"
    }
  }
}
```